US 12,390,451 B2
Small molecule inhibitor of the JAK family of kinases
Edward F. Attiyeh, Villanova, PA (US); Kurtis E. Bachman, Chester Springs, PA (US); Gerald C. Chu, Philadelphia, PA (US); Tatiana Koudriakova, Poway, CA (US); David C. Polidori, Rancho Santa Fe, CA (US); and Gary V. Borzillo, Upper Gwynedd, PA (US)
Assigned to Janssen Pharmaceutica NV, Beerse (BE)
Filed by Janssen Pharmaceutica NV, Beerse (BE)
Filed on Mar. 9, 2022, as Appl. No. 17/690,380.
Claims priority of provisional application 63/232,356, filed on Aug. 12, 2021.
Claims priority of provisional application 63/167,287, filed on Mar. 29, 2021.
Claims priority of provisional application 63/159,726, filed on Mar. 11, 2021.
Prior Publication US 2022/0288041 A1, Sep. 15, 2022
Int. Cl. A61K 31/437 (2006.01); A61K 45/06 (2006.01); A61P 1/00 (2006.01); A61P 35/00 (2006.01); C12Q 1/6886 (2018.01)
CPC A61K 31/437 (2013.01) [A61K 45/06 (2013.01); A61P 1/00 (2018.01); A61P 35/00 (2018.01); C12Q 1/6886 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/156 (2013.01); C12Q 2600/158 (2013.01)] 12 Claims
 
1. A method of treating familial adenomatous polyposis in a subject in need thereof comprising administering to the subject a composition comprising about 75 mg of compound of Formula I or a pharmaceutically acceptable salt thereof twice daily

OG Complex Work Unit Chemistry